Locations:
Search IconSearch
October 22, 2018/Cancer/Research

Which Breast Reconstruction Technique Is Best for Patients Undergoing Post-Mastectomy Radiation Therapy?

10-year outcomes favor autologous over implant

rad-treatment_650x450

Radiation therapy and breast reconstruction after mastectomy don’t always go well together. Rates of infection, dehiscence, skin and/or flap necrosis, and hematoma are higher in patients that undergo reconstruction and have post-mastectomy radiation therapy. In those patients that have reconstruction with a tissue expander/implant (TE/I), radiation is associated with higher rates of implant extrusion, leak or capsular contracture, while those that have autologous reconstruction (AR) are at risk for hernias as well.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Toxicity profiles vary by technique and timing, and data currently available in the literature provide little guidance on determining the optimal treatment approach, says Chirag Shah, MD, Director of Clinical Research and Breast Radiation Oncology in Cleveland Clinic’s Department of Radiation Oncology.

In response, Dr. Shah and colleagues at Cleveland Clinic recently compared rates of complications in patients who had post-mastectomy radiation therapy both before and after AR or TE/I.

“We suspected that radiation to a TE/I, regardless of timing, would portend worse outcomes,” says Dr. Shah. “Our study confirmed this. For patients requiring radiation after mastectomy, AR was associated with fewer trips back to the operating room for complications and fewer reconstruction failures.”

Results of this study will be shared in an oral presentation at the 2018 ASTRO Annual Meeting in San Antonio.

Comparing techniques and timing

The study included 230 patients that had 233 breast reconstructions. The patients had either AR or TE/I, either before or after radiation therapy, between 2000 and 2008. Median follow-up was 7.6 years. Age, BMI, and rates of active smoking, diabetes and hypertension were similar among the groups. Reconstruction was performed at the time of mastectomy, before radiation therapy, in 81 percent of patients.

Overall, rates of reconstruction failure (resulting in converting to another reconstruction technique or a flat chest wall) and complications requiring re-operation were significantly higher with TE/I as compared to AR (Table).

Advertisement

Table listing rates of reconstruction failure and complications requiring re-operation.

On multivariate analysis, the most significant predictors of complications requiring re-operation were:

  • TE/I (Odds Ratio 2.4; P = 0.007).
  • BMI ≥ 30 (Odds Ratio 3.4; P = 0.002).
  • Active smoking (Odds Ratio 2.7; P = 0.002).

The only significant predictor of reconstruction failure was TE/I (Odds Ratio 5.4; P < 0.001).

However, the rate of failure was not significantly different between the four groups when wound infection was excluded (P = 0.156).

Most complications requiring re-operation occurred within the first two years following treatment, but reconstruction failure occurred up to 10 years after reconstruction.

Rethinking the paradigm

“Many patients undergoing mastectomy get expanders and/or implants whether or not they have radiation therapy,” says Dr. Shah. “We may need to rethink that paradigm.”

These findings indicate that radiation therapy in patients with AR results in fewer complications and reconstruction failures than radiation therapy in patients with TE/I. Yet risk of failure with TE/I can be reduced by minimizing risk of infection.

Radiation oncologists should discuss treatment options in a multidisciplinary, collaborative group with breast surgeons and plastic surgeons, ensuring plans are in place for managing reconstruction risks, says Dr. Shah.

Advertisement

Related Articles

Physician checking patient's heart rate
July 15, 2026/Cancer

First-Generation BTK Inhibitors Associated with Higher Risk of Cardiac Events

Patients on ibrutinib were more than twice as likely to experience atrial fibrillation or heart failure than those on second-generation alternatives.

Thyroid cancer illustration
July 13, 2026/Cancer/News & Insight

New ASCO Guidelines Help Clinicians Navigate Rapid Shifts in Thyroid Cancer Treatment

Expert recommendations introduce use of targeted agents

AML cells in blood flow
July 10, 2026/Cancer/Blood Cancers

Ziftomenib + Chemotherapy Drives Deep Remission in Frontline NPM1-m/KMT2A-r AML

Combination therapy may soon represent new standard of care

Researcher with microscope
June 26, 2026/Cancer

Testosterone May Offer Anti-Tumor Activity in Glioblastoma

Research findings offer clues for improving disease outcomes in men

Male patient with doctor
June 17, 2026/Cancer/Patient Support

Overcoming Taboos: Helping Men with Cancer Restore Sexual Health

Creating a safe space for patients

Masked patient with physician
June 15, 2026/Cancer/Patient Support

Managing Infection Risk in the Era of Cell Therapy

Long-term immune effects reshape preventative strategies and timelines

Immune checkpoint inhibitor illustration
June 12, 2026/Cancer/News & Insight

Immunotherapy Appears to Reduce the Risk of Secondary Primary Cancers

Large-scale database also reveals potential for immunotherapy to protect against cancer

T53 mutation illustration
June 10, 2026/Cancer/News & Insight

TP53 Mutation Acquisition Timing Influences Prognosis in Myeloproliferative Neoplasms

Findings may help guide discussions around prognosis and allogeneic stem cell transplantation

Ad